Validation of the Japanese version of MemScreen: a rapid screening tool for mild cognitive impairment.

Ai IKEDA; Hadrien CHARVAT; Takeshi TANIGAWA; Nobuto SHIBATA; Koutatsu MARUYAMA; Kiyohide TOMOOKA; Yukari ASAI; Juna KAMIJIMA; Qisheng LI; Noemi ENDO; Saori MIYAZAKI; Archana SINGH-MANOUX; Julien DUMURGIER

Return

Validation of the Japanese version of MemScreen: a rapid screening tool for mild cognitive impairment.

Author: Ai IKEDA ¹ ; Hadrien CHARVAT ¹ ; Takeshi TANIGAWA ¹ ; Nobuto SHIBATA ² ; Koutatsu MARUYAMA ¹ ; Kiyohide TOMOOKA ¹ ; Yukari ASAI ¹ ; Juna KAMIJIMA ¹ ; Qisheng LI ¹ ; Noemi ENDO ² ; Saori MIYAZAKI ³ ; Archana SINGH-MANOUX ⁴ ; Julien DUMURGIER ⁴
Author Information

1. Department of Public Health, Graduate School of Medicine, Juntendo University.
2. Mental Health Clinic, Juntendo Tokyo Koto Geriatric Medical Center.
3. Graduate School of Agriculture, Ehime University.
4. Université Paris Cité, Inserm U1153, Epidemiology of Ageing & Neurodegenrative Diseases.
Publication Type:Validation Study
Keywords: Mild cognitive impairment; Screening; Validation study
MeSH: Humans; Cognitive Dysfunction/diagnosis*; Aged; Aged, 80 and over; Male; Female; Japan; Neuropsychological Tests; Middle Aged; Mass Screening/methods*; Sensitivity and Specificity; Reproducibility of Results; East Asian People
From:Environmental Health and Preventive Medicine 2025;30():96-96
CountryJapan
Language:English
Abstract: This study was to examine the validity of the Japanese version of MemScreen (MemScreen-J), a touchscreen MCI screening test. 20 patients with MCI aged 65-90 years at the Juntendo Tokyo Koto Geriatric Medical Center were recruited as cases in December 2023. Non-cases were recruited from local residents in Toon City, Ehime Prefecture in February 2024 and 40 residents, without a medical history of MCI, aged 58-84 years were included in the present study. MemScreen-J test, a self-administered screening test in the form of a digital application, downloadable on a tablet, was administered to participants to assess their cognitive function. Defining the group at high risk of MCI based on a MemScreen-J test score of 28 or lower achieved the best Youden index in the study sample, with a sensitivity of 0.75 and a specificity of 0.98. MemScreen-J appeared to be a valid screening tool among persons at the prodromal stage of dementia, given reasonably high accuracy in detection of MCI. This innovative neuropsychological test could be the first step in a diagnostic approach to cognitive complaints in a community, identifying persons at the preclinical stage of dementia.